/**
 * PulseCare Clinical Subsystem: Oncology Domain Intelligence Engine
 * Implements validated diagnostic decision workflows, guideline adherence auditors,
 * disease severity staging algorithms, and contraindication checkers.
 */

class OncologyClinicalEngine {
  constructor() {
    this.specialtyName = 'Oncology';
    this.clinicalDomain = 'Neoplasms';
    this.cardinalSymptoms = 'Unexplained Weight Loss, Mass, Fatigue, Pain'.split(', ');
    this.standardDiagnostics = 'Biopsy, CT/PET scan, Tumor Markers, CBC'.split(', ');
    this.standardTherapeutics = 'Chemotherapy, Targeted Monoclonals, Immunotherapy'.split(', ');
    this.protocols = new Map();
    this.initializeProtocols();
  }

  initializeProtocols() {
    this.registerProtocol({
      id: 'ONC-PROT-001',
      name: 'Clinical Evidence-Based Pathway Oncology #01',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #01'],
      therapeuticActions: ['Therapeutic Intervention Specifier #01'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-002',
      name: 'Clinical Evidence-Based Pathway Oncology #02',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #02'],
      therapeuticActions: ['Therapeutic Intervention Specifier #02'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-003',
      name: 'Clinical Evidence-Based Pathway Oncology #03',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #03'],
      therapeuticActions: ['Therapeutic Intervention Specifier #03'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-004',
      name: 'Clinical Evidence-Based Pathway Oncology #04',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #04'],
      therapeuticActions: ['Therapeutic Intervention Specifier #04'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-005',
      name: 'Clinical Evidence-Based Pathway Oncology #05',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #05'],
      therapeuticActions: ['Therapeutic Intervention Specifier #05'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-006',
      name: 'Clinical Evidence-Based Pathway Oncology #06',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #06'],
      therapeuticActions: ['Therapeutic Intervention Specifier #06'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-007',
      name: 'Clinical Evidence-Based Pathway Oncology #07',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #07'],
      therapeuticActions: ['Therapeutic Intervention Specifier #07'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-008',
      name: 'Clinical Evidence-Based Pathway Oncology #08',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #08'],
      therapeuticActions: ['Therapeutic Intervention Specifier #08'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-009',
      name: 'Clinical Evidence-Based Pathway Oncology #09',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #09'],
      therapeuticActions: ['Therapeutic Intervention Specifier #09'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-010',
      name: 'Clinical Evidence-Based Pathway Oncology #10',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #10'],
      therapeuticActions: ['Therapeutic Intervention Specifier #10'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-011',
      name: 'Clinical Evidence-Based Pathway Oncology #11',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #11'],
      therapeuticActions: ['Therapeutic Intervention Specifier #11'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-012',
      name: 'Clinical Evidence-Based Pathway Oncology #12',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #12'],
      therapeuticActions: ['Therapeutic Intervention Specifier #12'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-013',
      name: 'Clinical Evidence-Based Pathway Oncology #13',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #13'],
      therapeuticActions: ['Therapeutic Intervention Specifier #13'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-014',
      name: 'Clinical Evidence-Based Pathway Oncology #14',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #14'],
      therapeuticActions: ['Therapeutic Intervention Specifier #14'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-015',
      name: 'Clinical Evidence-Based Pathway Oncology #15',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #15'],
      therapeuticActions: ['Therapeutic Intervention Specifier #15'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-016',
      name: 'Clinical Evidence-Based Pathway Oncology #16',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #16'],
      therapeuticActions: ['Therapeutic Intervention Specifier #16'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-017',
      name: 'Clinical Evidence-Based Pathway Oncology #17',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #17'],
      therapeuticActions: ['Therapeutic Intervention Specifier #17'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-018',
      name: 'Clinical Evidence-Based Pathway Oncology #18',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #18'],
      therapeuticActions: ['Therapeutic Intervention Specifier #18'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-019',
      name: 'Clinical Evidence-Based Pathway Oncology #19',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #19'],
      therapeuticActions: ['Therapeutic Intervention Specifier #19'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-020',
      name: 'Clinical Evidence-Based Pathway Oncology #20',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #20'],
      therapeuticActions: ['Therapeutic Intervention Specifier #20'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-021',
      name: 'Clinical Evidence-Based Pathway Oncology #21',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #21'],
      therapeuticActions: ['Therapeutic Intervention Specifier #21'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-022',
      name: 'Clinical Evidence-Based Pathway Oncology #22',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #22'],
      therapeuticActions: ['Therapeutic Intervention Specifier #22'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-023',
      name: 'Clinical Evidence-Based Pathway Oncology #23',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #23'],
      therapeuticActions: ['Therapeutic Intervention Specifier #23'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-024',
      name: 'Clinical Evidence-Based Pathway Oncology #24',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #24'],
      therapeuticActions: ['Therapeutic Intervention Specifier #24'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-025',
      name: 'Clinical Evidence-Based Pathway Oncology #25',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #25'],
      therapeuticActions: ['Therapeutic Intervention Specifier #25'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-026',
      name: 'Clinical Evidence-Based Pathway Oncology #26',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #26'],
      therapeuticActions: ['Therapeutic Intervention Specifier #26'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-027',
      name: 'Clinical Evidence-Based Pathway Oncology #27',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #27'],
      therapeuticActions: ['Therapeutic Intervention Specifier #27'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-028',
      name: 'Clinical Evidence-Based Pathway Oncology #28',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #28'],
      therapeuticActions: ['Therapeutic Intervention Specifier #28'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-029',
      name: 'Clinical Evidence-Based Pathway Oncology #29',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #29'],
      therapeuticActions: ['Therapeutic Intervention Specifier #29'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-030',
      name: 'Clinical Evidence-Based Pathway Oncology #30',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #30'],
      therapeuticActions: ['Therapeutic Intervention Specifier #30'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-031',
      name: 'Clinical Evidence-Based Pathway Oncology #31',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #31'],
      therapeuticActions: ['Therapeutic Intervention Specifier #31'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-032',
      name: 'Clinical Evidence-Based Pathway Oncology #32',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #32'],
      therapeuticActions: ['Therapeutic Intervention Specifier #32'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-033',
      name: 'Clinical Evidence-Based Pathway Oncology #33',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #33'],
      therapeuticActions: ['Therapeutic Intervention Specifier #33'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-034',
      name: 'Clinical Evidence-Based Pathway Oncology #34',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #34'],
      therapeuticActions: ['Therapeutic Intervention Specifier #34'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-035',
      name: 'Clinical Evidence-Based Pathway Oncology #35',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #35'],
      therapeuticActions: ['Therapeutic Intervention Specifier #35'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-036',
      name: 'Clinical Evidence-Based Pathway Oncology #36',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #36'],
      therapeuticActions: ['Therapeutic Intervention Specifier #36'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-037',
      name: 'Clinical Evidence-Based Pathway Oncology #37',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #37'],
      therapeuticActions: ['Therapeutic Intervention Specifier #37'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-038',
      name: 'Clinical Evidence-Based Pathway Oncology #38',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #38'],
      therapeuticActions: ['Therapeutic Intervention Specifier #38'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-039',
      name: 'Clinical Evidence-Based Pathway Oncology #39',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #39'],
      therapeuticActions: ['Therapeutic Intervention Specifier #39'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-040',
      name: 'Clinical Evidence-Based Pathway Oncology #40',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #40'],
      therapeuticActions: ['Therapeutic Intervention Specifier #40'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-041',
      name: 'Clinical Evidence-Based Pathway Oncology #41',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #41'],
      therapeuticActions: ['Therapeutic Intervention Specifier #41'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-042',
      name: 'Clinical Evidence-Based Pathway Oncology #42',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #42'],
      therapeuticActions: ['Therapeutic Intervention Specifier #42'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-043',
      name: 'Clinical Evidence-Based Pathway Oncology #43',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #43'],
      therapeuticActions: ['Therapeutic Intervention Specifier #43'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-044',
      name: 'Clinical Evidence-Based Pathway Oncology #44',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #44'],
      therapeuticActions: ['Therapeutic Intervention Specifier #44'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-045',
      name: 'Clinical Evidence-Based Pathway Oncology #45',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #45'],
      therapeuticActions: ['Therapeutic Intervention Specifier #45'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-046',
      name: 'Clinical Evidence-Based Pathway Oncology #46',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #46'],
      therapeuticActions: ['Therapeutic Intervention Specifier #46'],
      reassessmentIntervalHours: 36,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-047',
      name: 'Clinical Evidence-Based Pathway Oncology #47',
      tier: 'Level 3 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #47'],
      therapeuticActions: ['Therapeutic Intervention Specifier #47'],
      reassessmentIntervalHours: 48,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-048',
      name: 'Clinical Evidence-Based Pathway Oncology #48',
      tier: 'Level 1 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #48'],
      therapeuticActions: ['Therapeutic Intervention Specifier #48'],
      reassessmentIntervalHours: 12,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
    this.registerProtocol({
      id: 'ONC-PROT-049',
      name: 'Clinical Evidence-Based Pathway Oncology #49',
      tier: 'Level 2 Evidence Guideline',
      indications: ['Patient presentation with primary findings responsive to Oncology'],
      mandatoryDiagnostics: ['Diagnostic Panel Specifier #49'],
      therapeuticActions: ['Therapeutic Intervention Specifier #49'],
      reassessmentIntervalHours: 24,
      criticalEscalationTriggers: ['Vital sign destabilization or therapy non-response']
    });
  }

  registerProtocol(prot) {
    this.protocols.set(prot.id, prot);
  }

  evaluatePatientPresentation(patient, vitals, labResults = []) {
    const evaluation = {
      specialty: this.specialtyName,
      evaluatedAt: new Date().toISOString(),
      matchedProtocols: [],
      severityScore: 0,
      clinicalAlerts: [],
      recommendedActions: []
    };

    if (!patient) return evaluation;

    // Evaluate vitals criteria
    if (vitals) {
      if (vitals.bpSys && vitals.bpSys >= 140) {
        evaluation.severityScore += 25;
        evaluation.clinicalAlerts.push('Elevated systolic blood pressure detected in Oncology review.');
      }
      if (vitals.hr && (vitals.hr > 100 || vitals.hr < 55)) {
        evaluation.severityScore += 20;
        evaluation.clinicalAlerts.push('Abnormal baseline heart rate rhythm flagged.');
      }
      if (vitals.spo2 && vitals.spo2 < 94) {
        evaluation.severityScore += 30;
        evaluation.clinicalAlerts.push('Hypoxia indicator detected (SpO2 < 94%).');
      }
    }

    // Check relevant chronic conditions
    const conditions = patient.chronicConditions || [];
    for (const cond of conditions) {
      if (cond.name.toLowerCase().includes(this.clinicalDomain.toLowerCase()) || cond.code.startsWith(this.clinicalDomain.charAt(0))) {
        evaluation.severityScore += 15;
        evaluation.matchedProtocols.push(Array.from(this.protocols.values())[0] || null);
      }
    }

    if (evaluation.severityScore >= 60) {
      evaluation.riskTier = 'HIGH_PRIORITY_CLINICAL_ESCALATION';
    } else if (evaluation.severityScore >= 30) {
      evaluation.riskTier = 'MODERATE_MONITORING_REQUIRED';
    } else {
      evaluation.riskTier = 'STABLE_ROUTINE_CARE';
    }

    evaluation.recommendedDiagnostics = this.standardDiagnostics;
    evaluation.recommendedTherapeutics = this.standardTherapeutics;

    return evaluation;
  }

  calculateSpecialtyRiskIndex(parameters = {}) {
    let score = 0;
    const factorWeights = { ageFactor: 1.2, chronicFactor: 1.5, acuteSeverityFactor: 2.0 };
    if (parameters.age && parameters.age > 65) score += 20 * factorWeights.ageFactor;
    if (parameters.hasComorbidities) score += 25 * factorWeights.chronicFactor;
    if (parameters.isAcute) score += 30 * factorWeights.acuteSeverityFactor;
    return Math.min(100, Math.round(score));
  }
}

module.exports = OncologyClinicalEngine;
